(3,4-dihydro-quinazolin-2-yl)-aryl-amines

Details (3,4-dihydro-quinazolin-2-yl)-aryl-amines (3,4-dihydro-quinazolin-2-yl)-aryl-amines

2006-03-08

2008-05-06

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S292000

Reexamination Certificate

active

07368454

ABSTRACT:
The present invention relates to methods for treating 5-HT5Areceptor related diseases which comprises administering compounds of formula IwhereinR1, R2, aryl, and n are defined in the specification and pharmaceutically acceptable acid addition salts thereof.

REFERENCES:
patent: 3496179 (1970-02-01), Hess et al.
patent: 3517005 (1970-06-01), Cronin et al.
patent: WO 2004/096771 (2004-11-01), None
Sprouse, J. “Pharmacological modulation of circadian rhythms . . . ” Expert Opin. Ther. Targets (2004), vol. 8, No. 1, pp. 25-38.
Hoyer, et al., Pharmacol. Rev. vol. 46, pp. 157-204 (1994).
Rees et al., FEBS Letters, vol. 355, pp. 242-246 (1994).
Francken et al., Eur. J. Pharmacol. vol. 361, pp. 299-309 (1998).
Noda, et al., J. Neurochem. vol. 84, pp. 222-232 (2003).
Dubertret et al., Journal of Psychiatric Research, vol. 38, pp. 371-376 (2004).
Garin, et al., Synthesis, pp. 375-376 (1983).
Garin, et al., Synthesis, p. 961 (1981).
Rahman, et al., Bioorganic & Medicinal Chemistry Letters, vol. 13, pp. 1119-1123 (2003).

Affiliated with

Also associated with

Rating

(3,4-dihydro-quinazolin-2-yl)-aryl-amines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with (3,4-dihydro-quinazolin-2-yl)-aryl-amines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (3,4-dihydro-quinazolin-2-yl)-aryl-amines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3986189